CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Year: 2022
R1 RCM to Present at the 41st Annual J.P. Morgan Health Care Conference
MURRAY, Utah, Dec. 22, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that...
MemorialCare Saddleback Medical Center Celebrated the Topping Out of $80M Innovative Women’s Health Pavilion
40,000-square-foot building opening in 2023, will transform women’s healthcare in south Orange County MemorialCare Saddleback Medical Center Celebrates the Forthcoming...
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complicationNEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE)...
Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program
INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – December 22, 2022, 10:10pm...
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying,...
Update on Proposed Acquisition of Grupo Somar
MIAMI and BARRANQUILLA, Colo., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a...
Galapagos announces changes to Executive Committee
Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee...
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life...
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
InnerScope Hearing Technologies (OTC: INND) Announces its HearingAssist Brand of FDA-Registered OTC Rechargeable Hearing Aids on CVS.com
InnerScope Launched its HearingAssist Brand of Over-the-Counter Rechargeable Hearing Aids on CVS.com and in Selected CVS Stores in Massachusetts and...
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank
PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH...
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2022
Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2022 (Pursuant to Article L.233-8 II of the...
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics , a clinical-stage drug discovery and development company focusing on novel...
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the...
BBS’s Management Meets with Minister of Economic Affairs and MP
BBS-Bioactive Bone Substitutes Plc, Investor News, 22 December 2022 at 3.45 p.m. The management team of BBS-Bioactive Bone Substitutes Plc...
Premier Health Reports Revenues of $80.5M for FY2022
MONTRÉAL, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech...
Novo Nordisk A/S:
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 22 December 2022 – On 4 November 2022, Novo Nordisk initiated...
Wellinks Adds Douglas Wenners to Board of Directors
Wenners Brings 25 Years of Health Plan Experience in Growth, Strategy, and InnovationNEW HAVEN, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE)...